[go: up one dir, main page]

CO2019002909A2 - Tratamientos de combinación que comprenden la administración de imidazopirazinonas - Google Patents

Tratamientos de combinación que comprenden la administración de imidazopirazinonas

Info

Publication number
CO2019002909A2
CO2019002909A2 CONC2019/0002909A CO2019002909A CO2019002909A2 CO 2019002909 A2 CO2019002909 A2 CO 2019002909A2 CO 2019002909 A CO2019002909 A CO 2019002909A CO 2019002909 A2 CO2019002909 A2 CO 2019002909A2
Authority
CO
Colombia
Prior art keywords
psychiatric
treatment
administration
compounds
combination treatments
Prior art date
Application number
CONC2019/0002909A
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Paulo Jorge Vieira Vital
Mikkel Jessing
Morten Langgård
Lars Kyhn Rasmussen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CO2019002909A2 publication Critical patent/CO2019002909A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Resumen La presente invención proporciona tratamientos de combinación que comprenden la administración de compuestos que son inhibidores de la enzima PDE1 y otros compuestos útiles en el tratamiento de trastornos psiquiátricos y/o cognitivos tales como, por ejemplo, el trastorno por déficit de atención con hiperactividad (TDAH), depresión, ansiedad, narcolepsia, esquizofrenia, deterioro cognitivo o deterioro cognitivo asociado con esquizofrenia (DCAE). Diferentes aspectos de la invención se refieren al uso combinado de dichos compuestos para el tratamiento de trastornos psiquiátricos y/o cognitivos. La presente invención también proporciona composiciones farmacéuticas que comprenden dichos inhibidores de la enzima PDE1 junto con otros compuestos útiles en el tratamiento de trastornos psiquiátricos y/o cognitivos.
CONC2019/0002909A 2016-10-28 2019-03-27 Tratamientos de combinación que comprenden la administración de imidazopirazinonas CO2019002909A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600659 2016-10-28
PCT/EP2017/077497 WO2018078038A1 (en) 2016-10-28 2017-10-26 Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Publications (1)

Publication Number Publication Date
CO2019002909A2 true CO2019002909A2 (es) 2019-06-19

Family

ID=60186299

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0002909A CO2019002909A2 (es) 2016-10-28 2019-03-27 Tratamientos de combinación que comprenden la administración de imidazopirazinonas

Country Status (30)

Country Link
US (1) US10905688B2 (es)
EP (1) EP3532064B1 (es)
JP (1) JP2019536762A (es)
KR (1) KR20190075068A (es)
CN (1) CN109803658A (es)
AR (1) AR109991A1 (es)
AU (1) AU2017350473A1 (es)
BR (1) BR112018013247A2 (es)
CA (1) CA3041607A1 (es)
CL (1) CL2019001091A1 (es)
CO (1) CO2019002909A2 (es)
CY (1) CY1123396T1 (es)
DK (1) DK3532064T3 (es)
ES (1) ES2816005T3 (es)
HR (1) HRP20201326T1 (es)
HU (1) HUE050403T2 (es)
IL (1) IL265635A (es)
LT (1) LT3532064T (es)
MA (1) MA46611B1 (es)
ME (1) ME03821B (es)
MX (1) MX2019004763A (es)
PL (1) PL3532064T3 (es)
PT (1) PT3532064T (es)
RS (1) RS60716B1 (es)
RU (1) RU2019109039A (es)
SG (1) SG11201903770UA (es)
SI (1) SI3532064T1 (es)
SM (1) SMT202000440T1 (es)
WO (1) WO2018078038A1 (es)
ZA (1) ZA201902091B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
DK3532064T3 (da) 2016-10-28 2020-08-24 H Lundbeck As Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
SG11202006916SA (en) 2018-02-01 2020-08-28 Japan Tobacco Inc Nitrogenated heterocyclic amide compound, and use thereof for medical purposes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
AU2004235915B2 (en) 2003-05-09 2010-08-05 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
MY147330A (en) 2007-05-11 2012-11-30 Pfizer Amino-heterocyclic compounds
WO2009068320A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
PL2603523T3 (pl) 2010-08-12 2016-07-29 Lilly Co Eli Przeciwciała przeciwko peptydowi amyloidu beta N3pGlu i ich zastosowania
US20120157458A1 (en) 2010-09-20 2012-06-21 Amy Ripka Imidazotriazinone compounds
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
AU2012323085B2 (en) * 2011-10-10 2017-03-09 H. Lundbeck A/S PDE9i with imidazo pyrazinone backbone
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
SG11201408397SA (en) 2012-06-18 2015-01-29 Dart Neuroscience Cayman Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
MX378194B (es) 2013-03-15 2025-03-10 Intra Cellular Therapies Inc Compuestos organicos.
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
EP3107897A1 (en) 2014-02-19 2016-12-28 H. Lundbeck A/S 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
CA2961186A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
TW201629064A (zh) * 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
WO2016147659A1 (en) 2015-03-16 2016-09-22 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) * 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
AU2016305275A1 (en) 2015-08-12 2018-02-08 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
CN105254635A (zh) * 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
DK3532064T3 (da) 2016-10-28 2020-08-24 H Lundbeck As Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones

Also Published As

Publication number Publication date
AU2017350473A1 (en) 2019-04-18
RU2019109039A (ru) 2020-11-30
AR109991A1 (es) 2019-02-13
CY1123396T1 (el) 2021-12-31
SMT202000440T1 (it) 2020-09-10
US10905688B2 (en) 2021-02-02
CL2019001091A1 (es) 2019-07-05
MX2019004763A (es) 2019-07-01
JP2019536762A (ja) 2019-12-19
HRP20201326T1 (hr) 2020-11-27
WO2018078038A1 (en) 2018-05-03
DK3532064T3 (da) 2020-08-24
LT3532064T (lt) 2020-09-25
PT3532064T (pt) 2020-09-03
BR112018013247A2 (pt) 2018-12-04
EP3532064B1 (en) 2020-07-29
HUE050403T2 (hu) 2020-12-28
ME03821B (me) 2021-04-20
US20190282571A1 (en) 2019-09-19
PL3532064T3 (pl) 2020-11-16
RS60716B1 (sr) 2020-09-30
SG11201903770UA (en) 2019-05-30
MA46611B1 (fr) 2020-08-31
ZA201902091B (en) 2020-10-28
CA3041607A1 (en) 2018-05-03
ES2816005T3 (es) 2021-03-31
IL265635A (en) 2019-05-30
MA46611A (fr) 2019-09-04
RU2019109039A3 (es) 2021-01-29
EP3532064A1 (en) 2019-09-04
CN109803658A (zh) 2019-05-24
KR20190075068A (ko) 2019-06-28
SI3532064T1 (sl) 2020-10-30

Similar Documents

Publication Publication Date Title
CO2019002909A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
CL2015002516A1 (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2015002655A1 (es) Moduladores de p2x7
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
NI201300073A (es) Compuestos y composiciones como inhibidores de la trk
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
CO6551721A2 (es) Moduladores de cinasa novedosos
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX379228B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
MX2021004925A (es) Variantes de adn-polimerasa modificadas.
BR112019024566A2 (pt) inibidores de pirazol magl
BR112017017970A2 (pt) composição de fragrância e combinação de fragrâncias
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras